← Back to Clinical Trials
Recruiting NCT07734506

NCT07734506 RELATIONSHIP BETWEEN ULTRASONOGRAPHIC QUADRICEPS MUSCLE THICKNESS AND SARCOPENIA MARKERS (HANDGRIP STRENGTH, SARC-F) AND KINESIOPHOBIA IN STROKE PATIENTS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07734506
Status Recruiting
Phase —
Sponsor Istanbul Physical Medicine Rehabilitation Training and Research Hospital
Condition Stroke
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2025-08-01
Primary Completion 2026-08-01

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2025-08-01 with a primary completion date of 2026-08-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to evaluate the relationship between ultrasonography-measured quadriceps muscle thickness and the sarcopenia markers SARC-F questionnaire and handgrip strength in patients diagnosed with ischemic stroke. In addition, the relationship between quadriceps muscle thickness and the level of kinesiophobia will be quantitatively assessed. This study is a cross-sectional clinical study conducted between August 1, 2025, and August 1, 2026, at the Physical Medicine and Rehabilitation Clinic of the University of Health Sciences İstanbul Physical Medicine and Rehabilitation Training and Research Hospital. Fifty volunteer participants with ischemic stroke and a lower-extremity Brunnstrom motor stage of 3 or higher, who presented to the clinic during the study period, were included. Bilateral quadriceps femoris muscle thickness, including the rectus femoris and vastus intermedius muscles, was measured using ultrasonography. The SARC-F questionnaire was used to assess sarcopenia risk, handgrip strength measurement was used to evaluate muscle strength, and the Tampa Scale for Kinesiophobia was used to determine the level of kinesiophobia. Motor recovery stage was assessed using the Brunnstrom Staging system; motor and cognitive independence were assessed using the Functional Independence Measure; walking independence was assessed using the Functional Ambulation Scale; and independence in activities of daily living was assessed using the Barthel Index of Activities of Daily Living. Because balance impairment, muscle weakness, and limited mobility are common after stroke, physical performance tests may be difficult to administer safely and consistently in this patient population. Therefore, the relationship between quadriceps muscle thickness and physical performance tests was not evaluated in this study. The Chair Stand Test, which requires repeated sit-to-stand movements as well as adequate balance and lower-extremity muscle strength, was also not included because it may increase the risk of falls in patients with limited mobility. This study aims to demonstrate the clinical potential of ultrasonography in the assessment of post-stroke sarcopenia and to support a more holistic approach to stroke rehabilitation planning that considers both physical and psychological factors.

Eligibility Criteria

Inclusion Criteria: * Chronic stroke duration between 6 months and 2 years * Ischemic stroke type * Age between 40-80 years * Brunnstrom lower extremity motor stage ≥3, ambulatory * Provision of written informed consent Exclusion Criteria: * Hemorrhagic stroke * Stroke onset more than 2 years prior * Inflammatory arthritis or other rheumatologic disease * History of knee trauma * Pre-stroke neurological gait disorder * Recurrent stroke * Lower extremity amputation * Knee joint contracture

Contact & Investigator

Central Contact

ALPEREN KOLUKISAOĞLU, MD

✉ drkolukisaoglu@gmail.com

📞 +905387911854

Principal Investigator

ALPEREN KOLUKISAOĞLU, MD

PRINCIPAL INVESTIGATOR

Istanbul Physical Medicine and Rehabilitation Training and Research Hospital

Frequently Asked Questions

Who can join the NCT07734506 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 80 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07734506 currently recruiting?

Yes, NCT07734506 is actively recruiting participants. Contact the research team at drkolukisaoglu@gmail.com for enrollment information.

Where is the NCT07734506 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07734506 clinical trial?

NCT07734506 is sponsored by Istanbul Physical Medicine Rehabilitation Training and Research Hospital. The principal investigator is ALPEREN KOLUKISAOĞLU, MD at Istanbul Physical Medicine and Rehabilitation Training and Research Hospital. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology